Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - oxybutynin hydrochloride - tablet - 5 milligram(s) - drugs for urinary frequency and incontinence; oxybutynin

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - oxybutynin hydrochloride - oral tablet - 5mg

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - oxybutynin hydrochloride - tablet - 3 milligram(s) - drugs for urinary frequency and incontinence; oxybutynin

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - oxybutynin hydrochloride - oral tablet - 3mg

Ireland - English - HPRA (Health Products Regulatory Authority)

j b tillotts limited - oxybutynin hydrochloride - tablets - 50 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-synthelabo ireland ltd - oxybutynin hydrochloride - tablets - 10 milligram

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 200 mg in 1 ml - acetylcysteine is the nonproprietary name for the n-acetyl derivative of the naturally occurring amino acid, l-cysteine. chemically, it is n-acetyl-l-cysteine. the compound is a white crystalline powder which melts in the range of 104° to 110°c and has a very slight odor. the structural formula of acetylcysteine is: c5 h9 no3 s                                                                                                      m.w.=163.19 acetylcysteine solution, usp is supplied as a sterile unpreserved solution (not for injection) in vials containing a 10% (100 mg/ml) or 20% (200 mg/ml) solution of acetylcysteine as the sodium salt. the inactive ingredients are edetate disodium, sodium hydroxide and sterile water for injection, usp. the ph of the solution ranges from 6.0 to 7.5. it is administered by inhalation or direct instillation for mucolysis, or orally for acetaminophen overdosage.

United States - English - NLM (National Library of Medicine)

hospira, inc. - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 100 mg in 1 ml - acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: chronic bronchopulmonary disease     (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) acute bronchopulmonary disease     (pneumonia, bronchitis, tracheobronchitis) pulmonary complications of cystic fibrosis tracheostomy care pulmonary complications associated with surgery use during anesthesia post-traumatic chest conditions atelectasis due to mucous obstruction diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) acetylcysteine is contraindicated in those patients who are sensitive to it. acetylcysteine, administered orally, is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen. it is essential to initiate treatment as soon as

United States - English - NLM (National Library of Medicine)

cardinal health 107, llc - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 200 mg in 1 ml - acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) pulmonary complications of cystic fibrosis tracheostomy care pulmonary complications associated with surgery use during anesthesia post-traumatic chest conditions atelectasis due to mucous obstruction diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) acetylcysteine is contraindicated in those patients who are sensitive to it. acetylcysteine, administered orally, is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen. it is essential to initiate treatment as soon as possible after the overdose and, in any case, within 24 hours of ingestion. there are no contraindications to oral administration of acetylcysteine in the treatment of acetaminophen overdose.

United States - English - NLM (National Library of Medicine)

american regent, inc. - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 100 mg in 1 ml - acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) pulmonary complications of cystic fibrosis tracheostomy care pulmonary complications associated with surgery use during anesthesia post-traumatic chest conditions atelectasis due to mucous obstruction diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) acetylcysteine is contraindicated in those patients who are sensitive to it. acetylcysteine, administered orally, is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen. it is essential to initiate treatment as soon as po